Volume 90 Issue 37 | p. 17 | Concentrates
Issue Date: September 10, 2012

Dainippon’s Sunovion Acquires Elevation

Department: Business
Keywords: pulmonary disease, milestones

Sunovion Pharmaceuticals has acquired Elevation Pharmaceuticals, a specialist in aerosol therapies for respiratory diseases. The acquisition includes Elevation’s EP-101, a long-acting bronchodilator in Phase II clinical trials for the treatment of chronic obstructive pulmonary disease. Sunovion, a subsidiary of Dainippon Sumitomo Pharma, will pay $100 million to Elevation’s shareholders plus developmental milestone payments of up to $90 million and commercial milestone payments of up to $210 million. Sunovion was called Sepracor until Dainippon Sumitomo acquired it in 2009.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment